Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
- MHLW Advisory Panel Backs Otsuka’s Schizophrenia Med Brexpiprazole and More
December 5, 2017
- Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
- Opdivo Earns Orphan Status for Malignant Pleural Mesothelioma
December 4, 2017
- MHLW Floats Incentives to Stem Antibiotic Overuse, but Payer Reps Negative: Chuikyo
December 4, 2017
- MHLW Presents Example of COI Management Guidelines for “Specified Clinical Research”
December 4, 2017
- CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch
December 4, 2017
- Keytruda Earns Lymphoma Nod, Novo’s Norditropin Label Expanded
December 1, 2017
- LDP Lawmakers Lash Out at Govt's Drug Pricing Proposals
December 1, 2017
- Full-Scale CEA Rollout to Be Delayed into FY2019: Official
December 1, 2017
- MHLW Looks to Lift Ban on Exports of Plasma Fraction Products by FY2020
December 1, 2017
- Abolish PMP or Narrow Down Its Scope: MOF Panel FY2018 Budget Recommendation
November 30, 2017
- Off-Year Revisions Should Be Confined to Limited Scope, JPWA Says at Chuikyo
November 30, 2017
- Regulators Will Be Involved in Safety Data Transition for LLP Withdrawals: MHLW Official
November 30, 2017
- MHLW to Announce Generic Usage Data by Insurers Twice Yearly Starting with FY2018 Data
November 30, 2017
- Exempt Some LLPs from New G1/G2 Price Scheme for Off-Patent Drugs: FPMAJ
November 30, 2017
- FPMAJ Chief Says Govt Proposal Is Fundamental Price Cut, Not Fundamental Reform: Chuikyo
November 30, 2017
- Maintain Drug Prices for Duration of Patent Coverage, PhRMA/EFPIA Stress at Chuikyo
November 30, 2017
- Japan, US, Europe Trade Groups Forge United Front against Govt PMP Plan, Supportive of Negative List: Chuikyo
November 30, 2017
- New Plan Would Reduce Number of PMP-Eligible Products by 40-50%: MHLW Estimate
November 29, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…